Physician profile
James E Mcnally
NPI 1568423895
$6,747.43
in general payments reported to CMS, 2019-2025
34 companies · $869 in 2025
The $869 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $710 · 2021: $763 · 2022: $1,152 · 2023: $1,404 · 2024: $842 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,115.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,417.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $864.05 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $733.60 | 2019-2023 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $607.76 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Allergan, INC. | $318.98 | 2020 | |
| Lilly USA, LLC | $256.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Ardelyx, INC. | $249.92 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $218.41 | 2020-2025 | |
| Indivior INC. | $196.12 | 2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.72 | 2023-2025 | Caplyta |
| Pfizer INC. | $153.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $144.01 | 2019-2025 | Gardasil 9, Vaxelis, Vaqta |
| Boston Scientific Corporation | $137.82 | 2025 | Intracept |
| Esperion Therapeutics, INC. | $135.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.99 | 2019-2023 | Jardiance |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcnally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.